ADC Therapeutics’ Post

🚀 Exciting Advances in DLBCL Treatment! 🚀 Healthcare professionals, explore the cutting-edge of oncology with BiTEs and CAR-T therapies for Diffuse Large B-cell Lymphoma (DLBCL). BiTEs engage the immune system by linking T-cells to cancer cells, offering a novel approach for relapsed/refractory cases. Meanwhile, CAR-T therapy personalizes the fight against cancer by engineering patient T-cells to target and destroy lymphoma cells. 🔍 Key Considerations: - Disease characteristics & patient-specific factors - Treatment availability & logistics - Efficacy and safety profiles Stay tuned for more updates as we navigate the future of hematological malignancy treatments together! #DLBCL #BiTEs #CARTtherapy #OncologyInnovation

Let’s take the fight against blood cancer to new heights! I am teaming up with The Leukemia & Lymphoma Society at Big Climb! If you would like to join me and Team ZS Associates reach our goal towards creating a world without blood cancer please click on the link: https://lnkd.in/e86Dj7Sh #BigClimb #ClimbConquerCure #BigClimb #ClimbConquerCure. #LetsDoThis!

📍 Cancer is an abnormal growth of cells. Cancer cells rapidly reproduce despite restriction of space, nutrients shared by other cells, or signals sent from the body to stop reproduction. ⚠️Oncology is the study of cancer and tumors. The term "cancer" is used when a tumor is malignant, which is to say it has the potential to cause harm, including death. 📍 Cancers are classified either according to the kind of fluid or tissue from which they originate, or according to the location in the body where they first developed. In addition, some cancers are of mixed types. 📍 The following five broad categories indicate the tissue and blood classifications of cancer: 1- Carcinoma (cancer in epithelial tissues) 2- Sarcoma (malignant tumor growing from connective tissues) 3- Lymphoma (cancer that originates in the nodes or glands of the lymphatic system) 4- Leukemia (blood cancer), and 5- Myeloma (cancer in plasma cells of bone marrow) 📹 Check out my detailed video about "different types of cancer": https://lnkd.in/e8SpSDQw 🟢 For amazing clinical pearls, you can join my WhatsApp group: 👇🏻 https://lnkd.in/d3axttDk 🔴 You can also follow me on "YouTube and Instagram" as well: YouTube👉🏼: https://lnkd.in/d4Fx3vCr Instagram👉🏼: https://lnkd.in/dy6krB4q #cancer #cancercare #cancerwarrior #cancerawareness #cancerday #chemotherapy #leukemia #lymphoma #myeloma #carcinoma #sarcoma #skincancer #bloodcancer #pharmacology #pharmacyeducation #medicaleducation #nursingeducation #mededucation #clinicalpharmacist

Conquer Lymphoma Cancer : Your Path to Recovery Your path to recovery serves as your beacon in the fight against Non-Hodgkin Lymphoma Cancer. This approach empowers you by blending top-notch medical care with whole-body therapies creating a full plan that fits your specific needs. By using cutting-edge treatments and making lifestyle shifts, you can take control of your health and build resilience. A committed team will stand by you helping you navigate this tough road with hope and self-assurance. Keep in mind, your inner strength and resolve play a crucial role in beating Lymphoma and getting back to a life full of health and energy. Use this as your guide to heal and move towards a brighter tomorrow. #ConquerLymphoma #LymphomaRecovery #CancerJourney #LymphomaAwareness #BeatCancer https://lnkd.in/eFy2Dgqb

Ryan Jacobs, the Director of Lymphoma at LEVINE CANCER INSTITUTE - CLEVELAND, presents in this MEDtalk an update on his research from the EHA 2023 meeting on AZD-0486, a novel CD19/CD3 T-cell engager used in treating relapsed refractory follicular lymphoma. The update includes patient responses and tolerability information, highlighting findings such as high overall response rates, complete remission rates, and low toxicity with the double step-up dosing method. 🔗Follow along as we cover EHA 2024: https://lnkd.in/dGGgc_CW #EHA24 #Lymphoma

The latest edition of ALLG News is now available! Visit https://lnkd.in/gXi_Ywqd to read about our progress and impact as we work towards better treatments and better lives through innovative treatments such as CAR-T cell therapy. Learn how vital these new blood cancer treatments are to patients and how the opening of impactful trials like the international NHL39 POLAR BEAR trial is making a difference for patients across Australia and New Zealand. ALLG is leading the way in clinical trial research and delivering new and improved blood cancer treatments for leukaemia, lymphoma, and myeloma. To support our research or to learn more, visit allg.org.au. #ALLG #ALLGtrials #bettertreatmentsbetterlives #clinicaltrials   #bloodcancer #bloodcancerawareness #bloodcancercure #bloodcancers #haematology #haematologyresearch #leukaemiaandlymphoma #myeloma #myelomaawareness

Ryan Jacobs, the Director of Lymphoma at Levine Cancer Institute - Cleveland, presents in this MEDtalk an update on his research from the EHA 2023 meeting on AZD-0486, a novel CD19/CD3 T-cell engager used in treating relapsed refractory follicular lymphoma. The update includes patient responses and tolerability information, highlighting findings such as high overall response rates, complete remission rates, and low toxicity with the double step-up dosing method. 🔗Follow along as we cover EHA 2024: https://lnkd.in/d8jmcNPw #EHA24 #Lymphoma

Did You Know?  Lymphoma Affects More than Just Lymph Nodes. Learn About Lymphoma, Its Type, and Its Diagnosis. What Questions Do You Have About This Cancer? Let's Keep the Conversation Going! At Saarthi Onco Care, We Stand as Your Beacon of Support in The Journey Against Lymphoma. #Saarthi #DrPriteshMunot #LymphomaAwareness #NavigatingLymphoma #CancerCareCompass #HopeAgainstCancer #SaarthiSupports #EmpowerWithKnowledge #LymphomaInsights #HolisticHealthJourney #CancerAwareness #FightCancer #CureCancer #CancerSurvivor #HopeAgainstCancer #TogetherWeFight #CancerCare #EndCancer #Lymphoma #NeverGiveUp #EarlyDetectionMatters #CancerFighter #LivingWithCancer #ThrivingBeyondCancer

Ryan Jacobs, the Director of Lymphoma at Levine Cancer Institute - Cleveland, presents in this MEDtalk an update on his research from the EHA 2023 meeting on AZD-0486, a novel CD19/CD3 T-cell engager used in treating relapsed refractory follicular lymphoma. The update includes patient responses and tolerability information, highlighting findings such as high overall response rates, complete remission rates, and low toxicity with the double step-up dosing method. 🔗Follow along as we cover EHA 2024: https://lnkd.in/d4be5h5W #EHA24 #Lymphoma

Ryan Jacobs, the Director of Lymphoma at Levine Cancer Institute - Cleveland, presents in this MEDtalk an update on his research from the EHA 2023 meeting on AZD-0486, a novel CD19/CD3 T-cell engager used in treating relapsed refractory follicular lymphoma. The update includes patient responses and tolerability information, highlighting findings such as high overall response rates, complete remission rates, and low toxicity with the double step-up dosing method. 🔗Follow along as we cover EHA 2024: https://lnkd.in/dPW-ansy  #EHA24 #Lymphoma